- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02532387
Outpatient Treatment of PE and DVT in the Emergency Department
Outpatient Treatment of Pulmonary Embolism and Deep Vein Thrombosis: Impact of a New Protocol on Emergency Department Efficiency and Patient Safety
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject is 18 years of age or older at time of enrollment.
- Subject is diagnosed with acute VTE (DVT or PE) in the MGH or BWH ED or transferred to the MGH or BWH ED (e.g from a clinic or outside hospital) with a diagnosis of acute VTE.
- Subject is treated as an outpatient (i.e. discharged) directly from the ED or admitted to the ED Observation Unit/ED Short Stay Unit on the outpatient treatment protocol.
Exclusion Criteria:
- Subjects admitted from the ED to an inpatient service will not be enrolled as study subjects, but will be used as contemporary controls.
- Subjects who are unable to understand or provide informed consent.
- Subjects unable or unlikely to follow up (e.g. prisoners).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
MGH ED/EDOU patients
Subjects who present to the Massachusetts General Hospital (MGH) ED or EDOU who meet all inclusion and no exclusion criteria. Intervention: Telephone follow-up at 7 and 30 days. |
Prospectively enrolled subjects will have a 7- and 30-day phone call.
|
|
BWH ED/EDOU patients
Subjects who present to the Brigham and Women's Hospital (BWH) ED or EDOU who meet all inclusion and no exclusion criteria. Intervention: Telephone follow-up at 7 and 30 days. |
Prospectively enrolled subjects will have a 7- and 30-day phone call.
|
|
Control subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficiency & cost of clinical protocol
Time Frame: Up to 30 days
|
To compare patients diagnosed with VTE after protocol implementation to those diagnosed with VTE prior to protocol implementation in terms of four measures of efficiency: A) ED length of stay - defined as time from ED registration to departure from the ED (to either the inpatient floor or to the EDOU). B) ED disposition time - defined as time from ED registration to bed request. C) Hospital length of stay - defined as time from ED registration to departure from the hospital. D) Cost - defined as the estimated cost of care including diagnostic testing, imaging, hospital inpatient/observation unit stay, medication/pharmacy costs. |
Up to 30 days
|
|
Safety of clinical protocol
Time Frame: Up to 30 days
|
To assess the safety of outpatient VTE treatment, specifically with regards to: A) recurrent venous thromboembolism; B) bleeding (major or minor); C) unscheduled return to hospital for any reason; D) death from any cause: occurring up to 30 days after their discharge. |
Up to 30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christopher Kabrhel, MD MPH, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015P000877
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deep Vein Thrombosis
-
University of OklahomaPfizerCompleted
-
University Medical Center GroningenCompletedSuspected Upper Extremity Deep Vein ThrombosisAustria, Netherlands, Italy, Belgium, Switzerland, Germany, United States
-
National Taiwan University HospitalUnknownUpper Extremity Deep Vein Thrombosis, SecondaryTaiwan
-
University of Missouri-ColumbiaTerminatedDEEP VEIN THROMBOSISUnited States
-
Vetex Medical Ltd.CompletedDeep Vein Thrombosis LegIreland, Germany, Bulgaria, United Kingdom
-
Children Hospital and Institute of Child Health...CompletedDeep Vein Thrombosis (DVT)Pakistan
-
Chinese PLA General HospitalRecruiting
-
UPECLIN HC FM Botucatu UnespCompletedProphylaxis of Deep Vein ThrombosisBrazil
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)CompletedSuspected Deep Vein ThrombosisCanada
-
Diakron PharmaceuticalsCompleted
Clinical Trials on Telephone follow-up
-
Aalborg University HospitalRecruiting
-
St. Justine's HospitalCompleted
-
Connolly Hospital BlanchardstownCompletedGeneral Surgery | Outpatients | Virtual Clinic | Text MessagingIreland
-
Union Hospital, Tongji Medical College, Huazhong...CompletedMucosal Melanoma | FDG PETChina
-
Zealand University HospitalEnrolling by invitationNon-Functional Pituitary AdenomaDenmark
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingPelvic Organ Prolapse (POP) | Stress Urinary Incontinence (SUI)China
-
Brandon UniversityRecruiting
-
University Hospital, ToulouseFondation de l'AvenirCompletedSwallowing DisordersFrance
-
University of Southern DenmarkUniversity Hospital, Gentofte, CopenhagenCompleted
-
Peking University Third HospitalRecruitingNon-specific Chronic Low Back PainChina